Medical Care
Global Omics Based Clinical Trials Market Research Report 2024
- Aug 28, 24
- ID: 515369
- Pages: 81
- Figures: 174
- Views: 2
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
The global Omics Based Clinical Trials market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Omics Based Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Omics Based Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Omics Based Clinical Trials in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Omics Based Clinical Trials include Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance and Rebus Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Omics Based Clinical Trials, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omics Based Clinical Trials.
Report Scope
The Omics Based Clinical Trials market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Omics Based Clinical Trials market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Omics Based Clinical Trials companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Omics Based Clinical Trials companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Omics Based Clinical Trials market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Omics Based Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Omics Based Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Omics Based Clinical Trials in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Omics Based Clinical Trials include Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance and Rebus Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Omics Based Clinical Trials, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omics Based Clinical Trials.
Report Scope
The Omics Based Clinical Trials market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Omics Based Clinical Trials market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Omics Based Clinical Trials companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Omics Based Clinical Trials companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Omics Based Clinical Trials Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Interventional Studies
1.2.3 Observational Studies
1.2.4 Expanded Access Studies
1.3 Market by Application
1.3.1 Global Omics Based Clinical Trials Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Respiratory Diseases
1.3.5 Skin Diseases
1.3.6 CNS Diseases
1.3.7 Immunology
1.3.8 Genetic Diseases
1.3.9 Other Indications
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Omics Based Clinical Trials Market Perspective (2019-2030)
2.2 Omics Based Clinical Trials Growth Trends by Region
2.2.1 Global Omics Based Clinical Trials Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Omics Based Clinical Trials Historic Market Size by Region (2019-2024)
2.2.3 Omics Based Clinical Trials Forecasted Market Size by Region (2025-2030)
2.3 Omics Based Clinical Trials Market Dynamics
2.3.1 Omics Based Clinical Trials Industry Trends
2.3.2 Omics Based Clinical Trials Market Drivers
2.3.3 Omics Based Clinical Trials Market Challenges
2.3.4 Omics Based Clinical Trials Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Omics Based Clinical Trials Players by Revenue
3.1.1 Global Top Omics Based Clinical Trials Players by Revenue (2019-2024)
3.1.2 Global Omics Based Clinical Trials Revenue Market Share by Players (2019-2024)
3.2 Global Omics Based Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Omics Based Clinical Trials Revenue
3.4 Global Omics Based Clinical Trials Market Concentration Ratio
3.4.1 Global Omics Based Clinical Trials Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Omics Based Clinical Trials Revenue in 2023
3.5 Omics Based Clinical Trials Key Players Head office and Area Served
3.6 Key Players Omics Based Clinical Trials Product Solution and Service
3.7 Date of Enter into Omics Based Clinical Trials Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Omics Based Clinical Trials Breakdown Data by Type
4.1 Global Omics Based Clinical Trials Historic Market Size by Type (2019-2024)
4.2 Global Omics Based Clinical Trials Forecasted Market Size by Type (2025-2030)
5 Omics Based Clinical Trials Breakdown Data by Application
5.1 Global Omics Based Clinical Trials Historic Market Size by Application (2019-2024)
5.2 Global Omics Based Clinical Trials Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Omics Based Clinical Trials Market Size (2019-2030)
6.2 North America Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Omics Based Clinical Trials Market Size by Country (2019-2024)
6.4 North America Omics Based Clinical Trials Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Omics Based Clinical Trials Market Size (2019-2030)
7.2 Europe Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Omics Based Clinical Trials Market Size by Country (2019-2024)
7.4 Europe Omics Based Clinical Trials Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Omics Based Clinical Trials Market Size (2019-2030)
8.2 Asia-Pacific Omics Based Clinical Trials Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2019-2024)
8.4 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Omics Based Clinical Trials Market Size (2019-2030)
9.2 Latin America Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Omics Based Clinical Trials Market Size by Country (2019-2024)
9.4 Latin America Omics Based Clinical Trials Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Omics Based Clinical Trials Market Size (2019-2030)
10.2 Middle East & Africa Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2019-2024)
10.4 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Parexel International Corporation
11.1.1 Parexel International Corporation Company Detail
11.1.2 Parexel International Corporation Business Overview
11.1.3 Parexel International Corporation Omics Based Clinical Trials Introduction
11.1.4 Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2019-2024)
11.1.5 Parexel International Corporation Recent Development
11.2 Pharmaceutical Product Development (PPD)
11.2.1 Pharmaceutical Product Development (PPD) Company Detail
11.2.2 Pharmaceutical Product Development (PPD) Business Overview
11.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Introduction
11.2.4 Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2019-2024)
11.2.5 Pharmaceutical Product Development (PPD) Recent Development
11.3 Charles River Laboratory
11.3.1 Charles River Laboratory Company Detail
11.3.2 Charles River Laboratory Business Overview
11.3.3 Charles River Laboratory Omics Based Clinical Trials Introduction
11.3.4 Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2019-2024)
11.3.5 Charles River Laboratory Recent Development
11.4 ICON plc
11.4.1 ICON plc Company Detail
11.4.2 ICON plc Business Overview
11.4.3 ICON plc Omics Based Clinical Trials Introduction
11.4.4 ICON plc Revenue in Omics Based Clinical Trials Business (2019-2024)
11.4.5 ICON plc Recent Development
11.5 SGS SA
11.5.1 SGS SA Company Detail
11.5.2 SGS SA Business Overview
11.5.3 SGS SA Omics Based Clinical Trials Introduction
11.5.4 SGS SA Revenue in Omics Based Clinical Trials Business (2019-2024)
11.5.5 SGS SA Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Detail
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Omics Based Clinical Trials Introduction
11.6.4 Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Omics Based Clinical Trials Introduction
11.7.4 Pfizer Revenue in Omics Based Clinical Trials Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Covance
11.8.1 Covance Company Detail
11.8.2 Covance Business Overview
11.8.3 Covance Omics Based Clinical Trials Introduction
11.8.4 Covance Revenue in Omics Based Clinical Trials Business (2019-2024)
11.8.5 Covance Recent Development
11.9 Rebus Bio
11.9.1 Rebus Bio Company Detail
11.9.2 Rebus Bio Business Overview
11.9.3 Rebus Bio Omics Based Clinical Trials Introduction
11.9.4 Rebus Bio Revenue in Omics Based Clinical Trials Business (2019-2024)
11.9.5 Rebus Bio Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Detail
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Omics Based Clinical Trials Introduction
11.10.4 Novo Nordisk Revenue in Omics Based Clinical Trials Business (2019-2024)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Omics Based Clinical Trials Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Interventional Studies
1.2.3 Observational Studies
1.2.4 Expanded Access Studies
1.3 Market by Application
1.3.1 Global Omics Based Clinical Trials Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Respiratory Diseases
1.3.5 Skin Diseases
1.3.6 CNS Diseases
1.3.7 Immunology
1.3.8 Genetic Diseases
1.3.9 Other Indications
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Omics Based Clinical Trials Market Perspective (2019-2030)
2.2 Omics Based Clinical Trials Growth Trends by Region
2.2.1 Global Omics Based Clinical Trials Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Omics Based Clinical Trials Historic Market Size by Region (2019-2024)
2.2.3 Omics Based Clinical Trials Forecasted Market Size by Region (2025-2030)
2.3 Omics Based Clinical Trials Market Dynamics
2.3.1 Omics Based Clinical Trials Industry Trends
2.3.2 Omics Based Clinical Trials Market Drivers
2.3.3 Omics Based Clinical Trials Market Challenges
2.3.4 Omics Based Clinical Trials Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Omics Based Clinical Trials Players by Revenue
3.1.1 Global Top Omics Based Clinical Trials Players by Revenue (2019-2024)
3.1.2 Global Omics Based Clinical Trials Revenue Market Share by Players (2019-2024)
3.2 Global Omics Based Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Omics Based Clinical Trials Revenue
3.4 Global Omics Based Clinical Trials Market Concentration Ratio
3.4.1 Global Omics Based Clinical Trials Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Omics Based Clinical Trials Revenue in 2023
3.5 Omics Based Clinical Trials Key Players Head office and Area Served
3.6 Key Players Omics Based Clinical Trials Product Solution and Service
3.7 Date of Enter into Omics Based Clinical Trials Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Omics Based Clinical Trials Breakdown Data by Type
4.1 Global Omics Based Clinical Trials Historic Market Size by Type (2019-2024)
4.2 Global Omics Based Clinical Trials Forecasted Market Size by Type (2025-2030)
5 Omics Based Clinical Trials Breakdown Data by Application
5.1 Global Omics Based Clinical Trials Historic Market Size by Application (2019-2024)
5.2 Global Omics Based Clinical Trials Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Omics Based Clinical Trials Market Size (2019-2030)
6.2 North America Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Omics Based Clinical Trials Market Size by Country (2019-2024)
6.4 North America Omics Based Clinical Trials Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Omics Based Clinical Trials Market Size (2019-2030)
7.2 Europe Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Omics Based Clinical Trials Market Size by Country (2019-2024)
7.4 Europe Omics Based Clinical Trials Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Omics Based Clinical Trials Market Size (2019-2030)
8.2 Asia-Pacific Omics Based Clinical Trials Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2019-2024)
8.4 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Omics Based Clinical Trials Market Size (2019-2030)
9.2 Latin America Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Omics Based Clinical Trials Market Size by Country (2019-2024)
9.4 Latin America Omics Based Clinical Trials Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Omics Based Clinical Trials Market Size (2019-2030)
10.2 Middle East & Africa Omics Based Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2019-2024)
10.4 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Parexel International Corporation
11.1.1 Parexel International Corporation Company Detail
11.1.2 Parexel International Corporation Business Overview
11.1.3 Parexel International Corporation Omics Based Clinical Trials Introduction
11.1.4 Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2019-2024)
11.1.5 Parexel International Corporation Recent Development
11.2 Pharmaceutical Product Development (PPD)
11.2.1 Pharmaceutical Product Development (PPD) Company Detail
11.2.2 Pharmaceutical Product Development (PPD) Business Overview
11.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Introduction
11.2.4 Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2019-2024)
11.2.5 Pharmaceutical Product Development (PPD) Recent Development
11.3 Charles River Laboratory
11.3.1 Charles River Laboratory Company Detail
11.3.2 Charles River Laboratory Business Overview
11.3.3 Charles River Laboratory Omics Based Clinical Trials Introduction
11.3.4 Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2019-2024)
11.3.5 Charles River Laboratory Recent Development
11.4 ICON plc
11.4.1 ICON plc Company Detail
11.4.2 ICON plc Business Overview
11.4.3 ICON plc Omics Based Clinical Trials Introduction
11.4.4 ICON plc Revenue in Omics Based Clinical Trials Business (2019-2024)
11.4.5 ICON plc Recent Development
11.5 SGS SA
11.5.1 SGS SA Company Detail
11.5.2 SGS SA Business Overview
11.5.3 SGS SA Omics Based Clinical Trials Introduction
11.5.4 SGS SA Revenue in Omics Based Clinical Trials Business (2019-2024)
11.5.5 SGS SA Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Detail
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Omics Based Clinical Trials Introduction
11.6.4 Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Omics Based Clinical Trials Introduction
11.7.4 Pfizer Revenue in Omics Based Clinical Trials Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Covance
11.8.1 Covance Company Detail
11.8.2 Covance Business Overview
11.8.3 Covance Omics Based Clinical Trials Introduction
11.8.4 Covance Revenue in Omics Based Clinical Trials Business (2019-2024)
11.8.5 Covance Recent Development
11.9 Rebus Bio
11.9.1 Rebus Bio Company Detail
11.9.2 Rebus Bio Business Overview
11.9.3 Rebus Bio Omics Based Clinical Trials Introduction
11.9.4 Rebus Bio Revenue in Omics Based Clinical Trials Business (2019-2024)
11.9.5 Rebus Bio Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Detail
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Omics Based Clinical Trials Introduction
11.10.4 Novo Nordisk Revenue in Omics Based Clinical Trials Business (2019-2024)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Omics Based Clinical Trials Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Interventional Studies
Table 3. Key Players of Observational Studies
Table 4. Key Players of Expanded Access Studies
Table 5. Global Omics Based Clinical Trials Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Omics Based Clinical Trials Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Omics Based Clinical Trials Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Omics Based Clinical Trials Market Share by Region (2019-2024)
Table 9. Global Omics Based Clinical Trials Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Omics Based Clinical Trials Market Share by Region (2025-2030)
Table 11. Omics Based Clinical Trials Market Trends
Table 12. Omics Based Clinical Trials Market Drivers
Table 13. Omics Based Clinical Trials Market Challenges
Table 14. Omics Based Clinical Trials Market Restraints
Table 15. Global Omics Based Clinical Trials Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Omics Based Clinical Trials Market Share by Players (2019-2024)
Table 17. Global Top Omics Based Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2023)
Table 18. Ranking of Global Top Omics Based Clinical Trials Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Omics Based Clinical Trials Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Omics Based Clinical Trials Product Solution and Service
Table 22. Date of Enter into Omics Based Clinical Trials Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Omics Based Clinical Trials Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Omics Based Clinical Trials Revenue Market Share by Type (2019-2024)
Table 26. Global Omics Based Clinical Trials Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Omics Based Clinical Trials Revenue Market Share by Type (2025-2030)
Table 28. Global Omics Based Clinical Trials Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Omics Based Clinical Trials Revenue Market Share by Application (2019-2024)
Table 30. Global Omics Based Clinical Trials Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Omics Based Clinical Trials Revenue Market Share by Application (2025-2030)
Table 32. North America Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Omics Based Clinical Trials Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Omics Based Clinical Trials Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Omics Based Clinical Trials Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 47. Parexel International Corporation Company Detail
Table 48. Parexel International Corporation Business Overview
Table 49. Parexel International Corporation Omics Based Clinical Trials Product
Table 50. Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 51. Parexel International Corporation Recent Development
Table 52. Pharmaceutical Product Development (PPD) Company Detail
Table 53. Pharmaceutical Product Development (PPD) Business Overview
Table 54. Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Product
Table 55. Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 56. Pharmaceutical Product Development (PPD) Recent Development
Table 57. Charles River Laboratory Company Detail
Table 58. Charles River Laboratory Business Overview
Table 59. Charles River Laboratory Omics Based Clinical Trials Product
Table 60. Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 61. Charles River Laboratory Recent Development
Table 62. ICON plc Company Detail
Table 63. ICON plc Business Overview
Table 64. ICON plc Omics Based Clinical Trials Product
Table 65. ICON plc Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 66. ICON plc Recent Development
Table 67. SGS SA Company Detail
Table 68. SGS SA Business Overview
Table 69. SGS SA Omics Based Clinical Trials Product
Table 70. SGS SA Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 71. SGS SA Recent Development
Table 72. Eli Lilly and Company Company Detail
Table 73. Eli Lilly and Company Business Overview
Table 74. Eli Lilly and Company Omics Based Clinical Trials Product
Table 75. Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 76. Eli Lilly and Company Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Omics Based Clinical Trials Product
Table 80. Pfizer Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Covance Company Detail
Table 83. Covance Business Overview
Table 84. Covance Omics Based Clinical Trials Product
Table 85. Covance Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 86. Covance Recent Development
Table 87. Rebus Bio Company Detail
Table 88. Rebus Bio Business Overview
Table 89. Rebus Bio Omics Based Clinical Trials Product
Table 90. Rebus Bio Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 91. Rebus Bio Recent Development
Table 92. Novo Nordisk Company Detail
Table 93. Novo Nordisk Business Overview
Table 94. Novo Nordisk Omics Based Clinical Trials Product
Table 95. Novo Nordisk Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 96. Novo Nordisk Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Omics Based Clinical Trials Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Omics Based Clinical Trials Market Share by Type: 2023 VS 2030
Figure 3. Interventional Studies Features
Figure 4. Observational Studies Features
Figure 5. Expanded Access Studies Features
Figure 6. Global Omics Based Clinical Trials Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Omics Based Clinical Trials Market Share by Application: 2023 VS 2030
Figure 8. Oncology Case Studies
Figure 9. Cardiology Case Studies
Figure 10. Respiratory Diseases Case Studies
Figure 11. Skin Diseases Case Studies
Figure 12. CNS Diseases Case Studies
Figure 13. Immunology Case Studies
Figure 14. Genetic Diseases Case Studies
Figure 15. Other Indications Case Studies
Figure 16. Omics Based Clinical Trials Report Years Considered
Figure 17. Global Omics Based Clinical Trials Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Omics Based Clinical Trials Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Omics Based Clinical Trials Market Share by Region: 2023 VS 2030
Figure 20. Global Omics Based Clinical Trials Market Share by Players in 2023
Figure 21. Global Top Omics Based Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Omics Based Clinical Trials Revenue in 2023
Figure 23. North America Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 25. United States Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 29. Germany Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Omics Based Clinical Trials Market Share by Region (2019-2030)
Figure 37. China Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 45. Mexico Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 49. Turkey Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Parexel International Corporation Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 52. Pharmaceutical Product Development (PPD) Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 53. Charles River Laboratory Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 54. ICON plc Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 55. SGS SA Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 56. Eli Lilly and Company Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 58. Covance Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 59. Rebus Bio Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 60. Novo Nordisk Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Omics Based Clinical Trials Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Interventional Studies
Table 3. Key Players of Observational Studies
Table 4. Key Players of Expanded Access Studies
Table 5. Global Omics Based Clinical Trials Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Omics Based Clinical Trials Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Omics Based Clinical Trials Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Omics Based Clinical Trials Market Share by Region (2019-2024)
Table 9. Global Omics Based Clinical Trials Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Omics Based Clinical Trials Market Share by Region (2025-2030)
Table 11. Omics Based Clinical Trials Market Trends
Table 12. Omics Based Clinical Trials Market Drivers
Table 13. Omics Based Clinical Trials Market Challenges
Table 14. Omics Based Clinical Trials Market Restraints
Table 15. Global Omics Based Clinical Trials Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Omics Based Clinical Trials Market Share by Players (2019-2024)
Table 17. Global Top Omics Based Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2023)
Table 18. Ranking of Global Top Omics Based Clinical Trials Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Omics Based Clinical Trials Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Omics Based Clinical Trials Product Solution and Service
Table 22. Date of Enter into Omics Based Clinical Trials Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Omics Based Clinical Trials Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Omics Based Clinical Trials Revenue Market Share by Type (2019-2024)
Table 26. Global Omics Based Clinical Trials Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Omics Based Clinical Trials Revenue Market Share by Type (2025-2030)
Table 28. Global Omics Based Clinical Trials Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Omics Based Clinical Trials Revenue Market Share by Application (2019-2024)
Table 30. Global Omics Based Clinical Trials Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Omics Based Clinical Trials Revenue Market Share by Application (2025-2030)
Table 32. North America Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Omics Based Clinical Trials Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Omics Based Clinical Trials Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Omics Based Clinical Trials Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Omics Based Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Omics Based Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Omics Based Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 47. Parexel International Corporation Company Detail
Table 48. Parexel International Corporation Business Overview
Table 49. Parexel International Corporation Omics Based Clinical Trials Product
Table 50. Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 51. Parexel International Corporation Recent Development
Table 52. Pharmaceutical Product Development (PPD) Company Detail
Table 53. Pharmaceutical Product Development (PPD) Business Overview
Table 54. Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Product
Table 55. Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 56. Pharmaceutical Product Development (PPD) Recent Development
Table 57. Charles River Laboratory Company Detail
Table 58. Charles River Laboratory Business Overview
Table 59. Charles River Laboratory Omics Based Clinical Trials Product
Table 60. Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 61. Charles River Laboratory Recent Development
Table 62. ICON plc Company Detail
Table 63. ICON plc Business Overview
Table 64. ICON plc Omics Based Clinical Trials Product
Table 65. ICON plc Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 66. ICON plc Recent Development
Table 67. SGS SA Company Detail
Table 68. SGS SA Business Overview
Table 69. SGS SA Omics Based Clinical Trials Product
Table 70. SGS SA Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 71. SGS SA Recent Development
Table 72. Eli Lilly and Company Company Detail
Table 73. Eli Lilly and Company Business Overview
Table 74. Eli Lilly and Company Omics Based Clinical Trials Product
Table 75. Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 76. Eli Lilly and Company Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Omics Based Clinical Trials Product
Table 80. Pfizer Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Covance Company Detail
Table 83. Covance Business Overview
Table 84. Covance Omics Based Clinical Trials Product
Table 85. Covance Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 86. Covance Recent Development
Table 87. Rebus Bio Company Detail
Table 88. Rebus Bio Business Overview
Table 89. Rebus Bio Omics Based Clinical Trials Product
Table 90. Rebus Bio Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 91. Rebus Bio Recent Development
Table 92. Novo Nordisk Company Detail
Table 93. Novo Nordisk Business Overview
Table 94. Novo Nordisk Omics Based Clinical Trials Product
Table 95. Novo Nordisk Revenue in Omics Based Clinical Trials Business (2019-2024) & (US$ Million)
Table 96. Novo Nordisk Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Omics Based Clinical Trials Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Omics Based Clinical Trials Market Share by Type: 2023 VS 2030
Figure 3. Interventional Studies Features
Figure 4. Observational Studies Features
Figure 5. Expanded Access Studies Features
Figure 6. Global Omics Based Clinical Trials Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Omics Based Clinical Trials Market Share by Application: 2023 VS 2030
Figure 8. Oncology Case Studies
Figure 9. Cardiology Case Studies
Figure 10. Respiratory Diseases Case Studies
Figure 11. Skin Diseases Case Studies
Figure 12. CNS Diseases Case Studies
Figure 13. Immunology Case Studies
Figure 14. Genetic Diseases Case Studies
Figure 15. Other Indications Case Studies
Figure 16. Omics Based Clinical Trials Report Years Considered
Figure 17. Global Omics Based Clinical Trials Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Omics Based Clinical Trials Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Omics Based Clinical Trials Market Share by Region: 2023 VS 2030
Figure 20. Global Omics Based Clinical Trials Market Share by Players in 2023
Figure 21. Global Top Omics Based Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Omics Based Clinical Trials Revenue in 2023
Figure 23. North America Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 25. United States Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 29. Germany Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Omics Based Clinical Trials Market Share by Region (2019-2030)
Figure 37. China Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 45. Mexico Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Omics Based Clinical Trials Market Share by Country (2019-2030)
Figure 49. Turkey Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Omics Based Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Parexel International Corporation Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 52. Pharmaceutical Product Development (PPD) Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 53. Charles River Laboratory Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 54. ICON plc Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 55. SGS SA Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 56. Eli Lilly and Company Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 57. Pfizer Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 58. Covance Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 59. Rebus Bio Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 60. Novo Nordisk Revenue Growth Rate in Omics Based Clinical Trials Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Camelina Seeds - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 11, 24
Bentgrass Seeds - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 11, 24
Barley Seeds - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 11, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232